search
OncoDaily
Trends
- 1Khalis Mustafayev on brain metastases biology in SCLC▼Khalis Mustafayev: The Biology of Brain Metastases and Emerging Therapeutic Strategies in SCLC
Oncodaily published an interview with oncologist Khalis Mustafayev discussing the biology of brain metastases in small cell lung cancer (SCLC) and new therapeutic strategies for the disease. The piece highlights how understanding metastatic mechanisms is shaping emerging treatment approaches in a cancer with limited options and high rates of brain spread.
- 2Yeva Margaryan's New Medical Journal Hits Pre-Launch Milestones▼Yeva Margaryan: Journal of Breakthroughs in Medicine and Science Reaches Key Pre-Launch Milestones
Yeva Margaryan's Journal of Breakthroughs in Medicine and Science has reportedly reached key milestones ahead of its launch, according to a report carried by Oncodaily. No further details about the journal's scope, editorial board, or launch date were provided, leaving its aims and backers largely unclear.
- 3OncoDaily and Natera to Host Webinar on Colorectal Cancer Surveillance▼OncoDaily and Natera to Host Webinar on Precision Medicine and MRD Surveillance in Colorectal Cancer
OncoDaily and Natera are set to host a webinar focused on precision medicine and molecular residual disease (MRD) surveillance in colorectal cancer. The session is expected to cover how circulating tumor DNA testing can guide treatment decisions and monitoring for patients after surgery. The announcement is being shared across oncology news channels as clinicians and researchers follow advances in MRD testing.
- 4
Oncodaily reports key insights from Mario Balsa at the ESMO 2026 congress. Balsa, a specialist in oncology pharmacy, is presented as offering takeaways from the European Society for Medical Oncology meeting. Further details on the specific findings or comments were not available.
- 5Itziar Canamasas on Tumor Biology in Precision Oncology▼Itziar Canamasas: Why Tumor Biology Matters in Precision Oncology
Oncodaily has published an interview with Itziar Canamasas exploring why tumor biology remains central to precision oncology. She argues that understanding the biological behavior of tumors is essential for matching patients to targeted therapies and improving treatment outcomes. The piece highlights how molecular and biological profiling continues to shape modern cancer care and personalized treatment decisions.
- 6PEACE-1 Trial Shows Long-Term Survival Benefit With Abiraterone▼Katy Beckermann։ PEACE-1 Trial Shows Long-Term Survival Benefit With Abiraterone in De Novo mCSPC
Dr. Katy Beckermann highlighted findings from the PEACE-1 trial showing that adding abiraterone to standard therapy provides a long-term survival benefit for men with de novo metastatic castration-sensitive prostate cancer. The update, reported by oncology news outlet Oncodaily, underscores growing evidence supporting intensified upfront treatment in this patient group, and is drawing attention among cancer specialists tracking evolving treatment standards.
- 7Arndt Vogel presents Phase I update for BGB-B2033 in advanced liver cancer●Arndt Vogel: Phase I Data Update for BGB-B2033 in Advanced HCC
Oncologist Arndt Vogel has shared an update on Phase I clinical trial data for BGB-B2033, an investigational drug being tested in patients with advanced hepatocellular carcinoma (HCC). The update, reported by oncology news outlet Oncodaily, offers new early-stage safety and efficacy findings for the compound. Early-phase results in liver cancer draw attention as treatment options for advanced disease remain limited.